Case report of non-arteritic ischemic optic neuropathy (NAION) associated with semaglutide use, adding to the growing pharmacovigilance evidence for this rare ocular adverse event.
Signal strengtheningEach new case of semaglutide-associated NAION strengthens the safety signal for this rare cause of sudden vision loss
What the researchers found
NAION case associated with semaglutide use, adding to the pharmacovigilance evidence for this rare adverse event.
Why it matters
Each NAION case report with semaglutide strengthens the safety signal. With millions of users, rare events need documentation.
How the study worked
Case report documenting NAION in a semaglutide user.
What this study cannot tell us
Single case. Cannot prove causation.
How to read the evidence
Case report. Low evidence level but important for pharmacovigilance.
When this study was published
Published in 2025.
The bigger picture
The semaglutide-NAION signal is building through accumulated case reports and database studies, requiring ongoing monitoring.
Questions still open
- How many NAION cases with semaglutide have been reported total?
- Should ophthalmologic screening be recommended for semaglutide users?
- Is the NAION risk dose-dependent?
Common questions
What is NAION?
Should I get my eyes checked on semaglutide?
Read the original research
Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.
Irish medical journal, 119(1), 13
Citation
Kelly, A; Hasif, A; McAnena, L; O'Brien, C. (2026). Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.. Irish medical journal, 119(1), 13.